Opdivo Gets Priority Review for NSCLC
BMS announced in a press release today that Opdivo (nivolumab), approved for advanced melanoma, has received priority review from the FDA for treating patients with advanced NSCLC.
In the U.S., lung cancer is one of the leading causes of cancer deaths. Non-small cell lung cancer, one of the most common types accounting for approximately 85% of cases, includes three main subtypes including squamous NSCLC. Squamous NSCLC accounts for approximately 25 to 30% of all lung cancers.
Read the complete press release:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025